M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Temsirolimus, Topotecan, and Bortezomib

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Torisel (Temsirolimus)
Drug: Hycamtin (Topotecan)
Drug: Velcade (Bortezomib)

First Posted Date: 2008-10-10

Last Posted Date: 2013-02-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT00770731

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer
Pancreatic Adenocarcinoma

Interventions: Drug: MK-0646
Drug: Gemcitabine
Drug: Erlotinib

First Posted Date: 2008-10-09

Last Posted Date: 2020-09-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 81

Registration Number: NCT00769483

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy

Phase 2

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Gemcitabine
Radiation: Radiation Therapy
Drug: Erlotinib
Procedure: Surgery

First Posted Date: 2008-10-06

Last Posted Date: 2016-05-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00766636

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver

Phase 2

Withdrawn

Conditions: Colon Cancer
Colorectal Cancer

Interventions: Drug: SIR-spheres Agent Administration
Drug: Cetuximab
Drug: Irinotecan

First Posted Date: 2008-10-03

Last Posted Date: 2013-01-03

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00766220

Adherence to Swallowing Exercises in Head and Neck Cancer

Conditions: Head and Neck Cancer

Interventions: Other: Brochure
Behavioral: Interview
Behavioral: Phone Call
Other: Questionnaire

First Posted Date: 2008-09-29

Last Posted Date: 2020-01-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 485

Registration Number: NCT00761397

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Doxil, Bevacizumab and Temsirolimus Trial

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Doxil
Drug: Bevacizumab
Drug: Temsirolimus

First Posted Date: 2008-09-29

Last Posted Date: 2019-04-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 200

Registration Number: NCT00761644

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Intrapleural Catheter Daily Versus Three Times a Week Drainage

Phase 2

Active, not recruiting

Conditions: Advanced Cancer
Pleural Effusion

Interventions: Procedure: Intrapleural catheter (IPC) drained
Procedure: IPC Placement
Radiation: Chest X-Ray

First Posted Date: 2008-09-29

Last Posted Date: 2024-10-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 257

Registration Number: NCT00761618

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia
Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2008-09-25

Last Posted Date: 2021-09-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 289

Registration Number: NCT00759798

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Lenalidomide
Drug: Rituximab

First Posted Date: 2008-09-25

Last Posted Date: 2015-08-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00759603

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Phase II Neoadjuvant in Inflammatory Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Lapatinib
Drug: Paclitaxel
Drug: 5-Fluorouracil (5-FU)
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2008-09-22

Last Posted Date: 2014-11-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00756470

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy